Implications of Phase 3 Trial Results Assessing Efficacy, Safety of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Name: Implications of Phase 3 Trial Results Assessing Efficacy, Safety of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
Uploaded: 2021-07-09T18:00:00.000Z
Description: Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.

July 9, 2021

Video

Conference|ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained the implications of the trial results on the treatment opportunities available for this patient population.